

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Keener et al.

Serial No.:

Filed: Herewith

For: SELECTIVE DESTRUCTION OF
CELLS INFECTED WITH HUMAN
IMMUNODEFICIENCY VIRUS

Examiner: J. Stucker

Group Art Unit: 3748

Attorney Docket No.: LIT-PI-529D1

CERTIFICATE OF MAILING

I hereby certify that this correspondence along with any attachments referred to or identified as being attached or enclosed is being deposited with the United States Postal Service as First Class Mail (under 37 C.F.R. § 1.8(a)) on the date of deposit shown below with sufficient postage and in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

7/10/03

Date of Deposit

Mandy Landon

Signature of registered practitioner or other person having reasonable basis to expect mailing to occur on date of deposit shown pursuant to 37 C.F.R. § 1.8(a)(1)(ii)

Mandy Landon

Typed/printed name of person whose signature is contained above

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:


In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO/SB/08 be considered by the Examiner and made of record. Copies of the listed documents are enclosed pursuant to 37 C.F.R. § 1.98(a).

In accordance with 37 C.F.R. § 1.97(g) and (h), filing of this Information Disclosure Statement is not to be construed as a representation that a search has been made or an admission that the information cited herein is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b). Further, no representation is made by Applicants herein that no other possible material information as defined in 37 C.F.R. § 1.56(b) exists.

Applicants offer to supply any explanation or discussion of the documents that the Examiner feels is necessary or desirable and which is requested.

This Information Disclosure Statement is filed before the first Office Action on Merits and no certification pursuant to 37 C.F.R. § 1.97(c) or a fee pursuant to 37 C.F.R. § 1.17(p) is required.

Respectfully submitted,



Stephen R. Christian
Registration No. 32,687
Attorney for Applicants
P.O. Box 1625
Idaho Falls, ID 83415-3899
Phone: (208) 526-9140
Fax: (208) 526-8339

Date: July 10, 2003
Enclosures: PTO/SB/08
Cited Documents

Form PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			ATTY. DOCKET NO. LIT-PI-529D1		SERIAL NO. Filed Herewith		
LIST OF ART CITED BY APPLICANT (Use several sheets if necessary)					APPLICANT William K. Keener				
					FILING DATE Filed Herewith		GROUP Unknown		
U.S. PATENT DOCUMENTS									
*Examiner Initial		Document Number	Date	Name		Class	Subclass	Filing Date If Appropriate	
	AA	5591829	01/07/97	Matsushita		530	391.1		
	AB	5633388	05/27/97	Diana et al		514	393		
	AC	5645836	07/08/97	Kitto		424	159.1		
	AD	5677274	10/14/97	Leppla et al		514	2		
	AE	5684024	11/04/97	Diana et al		548	365.4		
	AF	5767072	06/16/98	Vitetta et al		424	194.1		
	AG	5821243	10/13/98	Diana et al		544	238		
	AH	5830894	11/03/98	Pevcar et al		514	243		
	AI	5834599	11/10/98	Chang et al		530	388.35		
	AJ	5935957	8/10/99	Diana et al		514	247		
	AK	6333303	12/25/01	Borgford		514	2		
FOREIGN PATENT DOCUMENTS									
		Document Number	Date	Country		Class	Subclass	Translation	
	AL	WO97/41233	11/6/97	PCT				Yes	No
	AM								
	AN								
	AO								
	AP								
OTHER REFERENCES (including Author, Title, Date, Pertinent Pages, Etc.)									
	AR		Lord, J.M., et al, "Ricin: Structure, Mode of Action, and Some Current Applications", <u>The FASEB Journal</u> , Vol.8 pp. 201and 206, 2/94.						
			Richardson, P.T., et al, "Recombinant Prorcin Binds Galactose But Does Not Depurinate 28 S Ribosomal RNA," <u>FEBS</u> 07564, Vol 255, No. 1, page 15, 9/89.						
	AS		Westby, M.W., et al, "Preparation and Characterization of Recombinant, Prorcin Containing an Alternative Protease-Sensitive Linker Sequence," <u>Bioconjugate Chemistry</u> , 1992, 3, p. 375.						
			Darkel, P.L., et al., "Human Immunodeficiency Virus Protease," <u>Journal of Biological Chemistry</u> , Vol 264, No. 4, p. 2307 1989.						
	AT		Jordan, S.P., et al, "Activity and Dimerization of Human Immunodeficiency Virus Protease as a Function of Solvent Composition and Enzyme Concentration," <u>Journal of Biological Chemistry</u> , Vol. 267, No. 28, p. 20028. 1992.						
			Van Quen, M.G., "Rationale for the Use of Immunotoxins in the Treatment of HIV-Infected Humans," <u>Journal of Drug Targeting</u> , Vol 5, No. 2 p. 75, 1997.						
EXAMINER				DATE CONSIDERED					
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				ATTY. DOCKET NO. LIT-PI-529	SERIAL NO. Filed Herewith		
LIST OF ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT William K. Keener, et al			
				FILING DATE Filed Herewith	GROUP Unknown		
U.S. PATENT DOCUMENTS							
*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
FOREIGN PATENT DOCUMENTS							
		Document Number	Date	Country	Class	Subclass	Translation
							Yes
	AL						No
	AM						
	AN						
	AO						
	AP						
OTHER REFERENCES (including Author, Title, Date, Pertinent Pages, Etc.)							
	AR		Wachinger, M., et al, "Bryodin, a Single-Chain Ribosome-Inactivating Protein, Selectively Inhibits the Growth of HIV-1-Infected Cells and Reduces HIV-1 Production," <u>Research in Experimental Medicine</u> , 193:1-2, 1993.				
			Till, M.A., et al, "HIV-Infected Cells are Killed by rCF4-Ricin A Chain," <u>Science</u> , Vol. 24 p. 1166.				
	AS						
	AT						
EXAMINER				DATE CONSIDERED			
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>							